Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal Volunteers-Reference-Cited by-同舟云学术

Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal Volunteers

Published:2016-10-25 Issue:11 Volume:5 Page:617-624
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Kovalenko P¹,DiCioccio AT¹,Davis JD¹,Li M²,Ardeleanu M¹,Graham NMH¹,Soltys R¹

Affiliation:

1. Regeneron Pharmaceuticals, Inc.Tarrytown New York USA

2. Sanofi, BridgewaterNew Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12136

Reference16 articles.

1. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

2. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

3. Atopic Dermatitis

4. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

5. Approximations of the target-mediated drug disposition model and identifiability of model parameters

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity;Journal of the European Academy of Dermatology and Venereology;2024-07-31

2. Utility of Cellular Measurements of Non-Specific Endocytosis to Assess the Target-Independent Clearance of Monoclonal Antibodies;Journal of Pharmaceutical Sciences;2024-07

3. Utility of Cellular Measurements of Non-Specific Endocytosis to Assess the Target-Independent Clearance of Monoclonal Antibodies;2024-04-16

4. Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR‐1819 in healthy subjects: A randomized, controlled phase I study;Clinical and Translational Science;2024-03-28

5. Monoclonal Antibodies: From Structure to Therapeutic Application;Pharmaceutical Biotechnology;2024